No Clinically Significant Drug Interaction Between Ivermectin and Exemestane
There is no documented drug interaction between ivermectin and exemestane, and these medications can be used concurrently in a postmenopausal woman receiving exemestane for hormone-receptor-positive breast cancer.
Pharmacologic Rationale
The FDA prescribing information for exemestane 1 specifically addresses drug interactions and identifies only strong CYP3A4 inducers (such as rifampicin and phenytoin) as requiring dose adjustment. When exemestane is co-administered with strong CYP3A4 inducers, the dose should be increased from 25 mg to 50 mg once daily 1.
Ivermectin is not a strong CYP3A4 inducer and does not appear in the exemestane drug interaction warnings. While ivermectin is a substrate of CYP3A4, it does not significantly induce or inhibit this enzyme system at therapeutic doses.
Key Clinical Considerations
What to Monitor
- Continue standard exemestane monitoring: bone mineral density assessment, vitamin D levels, and routine surveillance for disease progression 1
- No dose adjustment of exemestane is needed when co-administered with ivermectin
- Avoid estrogen-containing agents which would interfere with exemestane's mechanism of action 1
Important Caveats
The exemestane FDA label 1 emphasizes avoiding co-administration with:
- Systemic estrogen-containing agents (interferes with pharmacologic action)
- Strong CYP3A4 inducers without dose adjustment
Ivermectin falls into neither category, making concurrent use safe from a drug interaction perspective.
Clinical Context
The ASCO guidelines 2, 3 provide comprehensive recommendations for exemestane use in hormone-receptor-positive breast cancer but do not identify ivermectin as a contraindicated or interacting medication. The primary concerns with exemestane therapy relate to bone health, vitamin D status, and appropriate patient selection based on prior endocrine therapy exposure—not drug interactions with antiparasitic agents.